Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

International study with sites in the Czech Republic and Poland
Non-Hodgkin's Lymphoma
DRUG: Interferon Gamma-1b|DRUG: Rituximab
time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes), 6 weeks
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

International study with sites in the Czech Republic and Poland